LuCE president, Stefania Vallone provided an insight analysis on “Being heard over the noise: The patient viewpoint” during #ESMO2018.
She emphasized the role can patients and patient organizations play within the new therapies development and reimbursement. According to her, in lung cancer, time matters for patient, thus early diagnosis is crucial for a good prognosis. Anyhow, with patients who do/have smoked, GPs often explore other diseases and consequent treatments.
She highlighted the importance of the last year’s Report focusing to access on treatment and the opportunity to continue this subject with access to clinical trials.